Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00194779
What this trial is testing

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerHER2-positive Breast Cancer+6 more
University of Washington 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06016738
What this trial is testing

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 510
Testing effectiveness (Phase 2)Study completedNCT00444535
What this trial is testing

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Not applicableLooking for participantsNCT07242118
What this trial is testing

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

Who this might be right for
Breast Cancer Female
University of Kansas Medical Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT06656624
What this trial is testing

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 190
Testing effectiveness (Phase 2)Study completedNCT03878823
What this trial is testing

Safety and Pharmacokinetics of ODM-209

Who this might be right for
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate Cancer+1 more
Orion Corporation, Orion Pharma 38
Testing effectiveness (Phase 2)Looking for participantsNCT05601440
What this trial is testing

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 484
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Study completedNCT03774472
What this trial is testing

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 15
Early research (Phase 1)Looking for participantsNCT05900895
What this trial is testing

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Who this might be right for
Metastatic Breast Cancer
Mary D Chamberlin 6
Testing effectiveness (Phase 2)UnknownNCT05004142
What this trial is testing

Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 70
Testing effectiveness (Phase 2)Ended earlyNCT02598310
What this trial is testing

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Negative NeoplasmHER-2 Positive Breast Cancer
Osaka Medical College 30
Testing effectiveness (Phase 2)WithdrawnNCT02685306
What this trial is testing

Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsTriple-Negative Breast Neoplasm+4 more
Peregrine Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Testing effectiveness (Phase 2)Study completedNCT01202591
What this trial is testing

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Who this might be right for
FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer
AstraZeneca 127
Not applicableStudy completedNCT00870168
What this trial is testing

Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Jean Perrin 60
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214288
What this trial is testing

Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Who this might be right for
Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)Ended earlyNCT01194869
What this trial is testing

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Emory University 25
Early research (Phase 1)Study completedNCT03455270
What this trial is testing

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast Cancer FemaleBreast Neoplasm+4 more
G1 Therapeutics, Inc. 107
Next Page